If the author’s manuscript is assessed as inappropriate to be published in his/her preferred journal, our editorial team may help the author in transferring the submission to a more appropriate Bentham Journal, through Bentham’s Manuscript Transfer Facility.
Transfer of Submission
Transfer of submission with Bentham’s Manuscript Transfer Facility is very simple.
The Author receives the transfer proposal by email - the transfer process is initiated by an affirmative response from the author to our transfer proposal.
The Authors’ manuscript is transferred to a suitable journal for initial editorial scrutiny.
The Author then receives an editorial decision from the journal.
Selection of another Journal
The Author is free to choose to submit the manuscript to a new journal by declining our transfer offer.
Our aim is to facilitate and develop rapid, effective and truly innovative solutions to facilitate our valued authors by enabling more options and better services to improve the publication process.
G. Aliev "GALLY" International Biomedical Research Consulting LLC San Antonio, TX (USA)
Dr. Gjumrakch Aliev, MD, PhD, President “GALLY” International Biomedical Research Institute Inc., San Antonio, Texas, USA. He also hold appointment with the University of Atlanta, as a Professor and as a Leading Scientist , Institute of Physiologically Active Compounds. Russian Academy of Sciences.
He received his MD in 1982, from the Baku Medical University (former USSR) with cum laude. Then he accomplished his PhD in Cardiovascular Diseases from the prestigious Russian Academy of the Medical Sciences, Moscow, Russia in 1988 with cum laude. He authored and coauthored more than 500 publications in the fields of neurodegenerative diseases research (Alzheimer disease), as well as cardio- and cerebrovascular disease, cancer, and electron microscopy.
Dr. Gregory received his bachelor’s and PhD degrees in chemistry from the University of Virginia and worked on the synthesis of complex indole alkaloids. In 1988, he joined Nova Pharmaceuticals Inc. He became the Vice President of Chemistry in 1997.
In 2002, as Vice-President, he joined Artesian Therapeutics in Gaithersburg and designed and patented an IND candidate in a year.
In 2005, he joined MGI PHARMA, as head of the medicinal chemistry. In 2007, he became the Senior Director of Intellectual Property, and in 2008, he worked as senior member of IP group